EMMA

Emmaus Life Sciences, Inc. [EMMA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

EMMA Stock Summary

Top 10 Correlated ETFs

EMMA

Top 10 Correlated Stocks

EMMA

In the News

EMMA Financial details

Company Rating
-
Market Cap
5.63M
Income
-4.74M
Revenue
28.46M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
54
Optionable
No
Shortable
Yes
Earnings
11 Apr 2024
P/E
-0.83
Forward P/E
-
PEG
0.12
P/S
0.14
P/B
-0.11
P/C
-
P/FCF
-4.49
Quick Ratio
0.1
Current Ratio
0.15
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.09
EPS next Y
-
EPS next Q
-
EPS this Y
-31.25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-54.34%
Revenue last 5Y
69.47%
Revenue Q/Q
-53.36%
EPS Q/Q
-104.29%
-
-
-
-
SMA20
-
SMA50
-33.33%
SMA100
-33.33%
Inst Own
-
Inst Trans
-
ROA
-10%
ROE
13%
ROC
-0.06%
Gross Margin
94%
Oper. Margin
3%
Profit Margin
-17%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.051-0.354
52W High
-
52W Low
-
RSI
39.73
Rel Volume
-
Avg Volume
18.57K
Volume
Perf Week
3.23%
Perf Month
-24.53%
Perf Quarter
-59.9%
Perf Half Y
-11.11%
-
-
-
-
Beta
1.703
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.016
Change
6.67%

Something similar

Top by Market Cap
FXAIX
AMZN
NVD.DE
FB2A.DE
BRYN.DE
Top Correlated ETFs
117680.KS
139240.KS
368680.KS
157490.KS
364960.KS
Top Correlated Stocks
010130.KS
098460.KQ
003030.KS
126560.KS
011790.KS
Similar Market Cap
AKMY.V
PEX
CLINE-B.ST
NEDSE.AS
HVT.L

Company Profile

Healthcare Biotechnology
  • Volume Average 18.57K
  • Market Capitalization 5.63M
  • Employee 54
  • CEO Mr. Willis C. Lee M.S.
  • Headquarters Torrance,CA,US
  • IPO Date 2000-05-09
  • Website https://www.emmausmedical.com

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.